Editor

Behind the News columnist

A native of Kentucky, Andrews has worked at Hoosier newspapers since graduating from Indiana University in 1987. He covered education at the Journal and Courier in Lafayette before joining IBJ in 1991. He later was a business reporter and the business editor of The Indianapolis Star. He’s been writing his Behind the News column for IBJ since rejoining the newspaper in 2000. Andrews and his wife, Kathleen, have a son in college and another living in Colorado. They live in the Nora area with their two dogs.

Articles

David Simon: Sky-is-falling perception ‘ridiculous’

A Wall Street analyst said turnover among retailers actually creates opportunity for Simon Property Group—enabling it to replace underperforming department stores with an eclectic mix of restaurants, movie theaters and other entertainment venues that pay higher rent and boost customer traffic.

Read More

Despite rich new TV deal, NCAA gets debt downgrade

The governing body for college sports weathered a $411 million deficit in its latest fiscal year. But long term, its financial position appears strong—in no small part because of an $8.8 billion TV contract extension it inked last year for its men's basketball tournament.

Read More
rop-hhgregg-060815-2col.jpg

HHGregg files for bankruptcy, lines up buyer

The company did not disclose the identity of the purchaser. CEO Robert Riesbeck said HHGregg is “fully committed” to continuing to operate the 132 stores that will remain after it completes the closings announced last week of 88 stores.

Read More

Holcomb’s HIP 2.0 waiver likely to sail through Washington

The Trump administration and its pick to lead the Centers for Medicare & Medicaid Services are likely to champion the approach behind HIP 2.0—a Medicaid expansion that requires those receiving insurance coverage to have "skin in the game" by contributing financially.

Read More

At Eli Lilly, tears, heartbreak and renewed determination

Eli Lilly and Co. employees knew the Alzheimer's treatment solanezumab was not a sure bet. But that didn’t make the pain any less acute after the company announced the drug had failed to demonstrate effectiveness during a 2,100-patient Phase 3 clinical trial.

Read More